文献速递浆细胞疾病

单药伊沙妥昔单抗(抗CD38单克隆抗体)治疗复发/难治性多发性骨髓瘤的剂量探索2期研究

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.
PubMed 文献 · Leukemia · 2020-05-14

这项2期剂量探索研究纳入97例复发/难治性多发性骨髓瘤患者,随机接受伊沙妥昔单抗3 mg/kg每2周、10 mg/kg每2周(2周期)后每4周、10 mg/kg每2周,第四组评估20 mg/kg每周(1周期)后每2周。总缓解率分别为4.3%、20.0%、29.2%和24.0%;≥10 mg/kg剂量组中位无进展生存期4.6个月、总生存期18.7个月,高危细胞遗传学患者总缓解率40.9%(9/22)。结论认为伊沙妥昔单抗在经重度治疗的复发/难治性多发性骨髓瘤中有活性且总体耐受良好,≥10 mg/kg剂量疗效最大。

要点

  • 伊沙妥昔单抗10 mg/kg及20 mg/kg方案总缓解率分别为29.2%、20.0%、24.0%,3 mg/kg组仅4.3%。
  • ≥10 mg/kg剂量组中位无进展生存期4.6个月,中位总生存期18.7个月。
  • 最常见非血液学不良事件为恶心34.0%、乏力32.0%、上呼吸道感染28.9%,多为≤2级。

核心结论

  • 伊沙妥昔单抗在经重度治疗的复发/难治性多发性骨髓瘤中有活性且总体耐受良好,≥10 mg/kg剂量疗效最大。

研究设计与样本

  • 2期剂量探索研究(NCT01084252),纳入97例既往≥3线治疗或对免疫调节药物和蛋白酶体抑制剂双重难治的复发/难治性多发性骨髓瘤患者。
  • 患者随机接受伊沙妥昔单抗3 mg/kg每2周、10 mg/kg每2周(2周期)后每4周、10 mg/kg每2周,第四组评估20 mg/kg每周(1周期)后每2周。
  • 患者中位(范围)年龄62岁(38-85),既往治疗线数中位5线(2-14),85%为双重难治。

主要发现

  • 总缓解率在伊沙妥昔单抗3 mg/kg每2周、10 mg/kg每2周/每4周、10 mg/kg每2周、20 mg/kg每周/每2周组分别为4.3%、20.0%、29.2%、24.0%。
  • ≥10 mg/kg剂量组中位无进展生存期4.6个月,中位总生存期18.7个月。
  • ≥10 mg/kg剂量组中高危细胞遗传学患者总缓解率为40.9%(9/22)。
  • 缓解者与未缓解者CD38受体密度相似。
  • 最常见非血液学不良事件(通常≤2级)为恶心34.0%、乏力32.0%、上呼吸道感染28.9%;输液反应发生率为51.5%(通常发生于首次输注且≤2级)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A Phase 2 dose-finding study evaluated isatuximab, an anti-CD38 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM; NCT01084252). Patients with ≥3 prior lines or refractory to both immunomodulatory drugs and proteasome inhibitors (dual refractory) were randomized to isatuximab 3 mg/kg every 2 weeks (Q2W), 10 mg/kg Q2W(2 cycles)/Q4W, or 10 mg/kg Q2W. A fourth arm evaluated 20 mg/kg QW(1 cycle)/Q2W. Patients (N = 97) had a median (range) age of 62 years (38-85), 5 (2-14) prior therapy lines, and 85% were double refractory. The overall response rate (ORR) was 4.3, 20.0, 29.2, and 24.0% with isatuximab 3 mg/kg Q2W, 10 mg/kg Q2W/Q4W, 10 mg/kg Q2W, and 20 mg/kg QW/Q2W, respectively. At doses ≥10 mg/kg, median progression-free survival and overall survival were 4.6 and 18.7 months, respectively, and the ORR was 40.9% (9/22) in patients with high-risk cytogenetics. CD38 receptor density was similar in responders and non-responders. The most common non-hematologic adverse events (typically grade ≤2) were nausea (34.0%), fatigue (32.0%), and upper respiratory tract infections (28.9%). Infusion reactions (typically with first infusion and grade ≤2) occurred in 51.5% of patients. In conclusion, isatuximab is active and generally well tolerated in heavily pretreated RRMM, with greatest efficacy at doses ≥10 mg/kg.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mikhael J, Richter J, Vij R, et al. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia. 2020. PMID: 32409691. doi:10.1038/s41375-020-0857-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。